STADA Arzneimittel AG
STADA Arzneimittel AG: STADA: Statement on media reports
DGAP-News: STADA Arzneimittel AG / Key word(s): Statement STADA confirms current media reports that the expert sessions which were planned as part of the structured bidding process have been postponed based on the decision of the Supervisory Board. The Executive Board and the Supervisory Board mutually agree that the indicative bids do not yet reflect the fundamental value of STADA. Thus, the company, for the time being, wants to provide the bidders the opportunity to increase their offers.
STADA objects current media reports that the delay in the process is aimed to make another committee composed of a private equity company and a strategic investor enter the process. Additional information for journalists: STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad Vilbel – Germany / Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: press@stada.de Or visit us in the Internet at www.stada.com.
16.03.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | STADA Arzneimittel AG |
Stadastraße 2-18 | |
61118 Bad Vilbel | |
Germany | |
Phone: | +49 (0)6101 603- 113 |
Fax: | +49 (0)6101 603- 506 |
E-mail: | communications@stada.de |
Internet: | www.stada.de |
ISIN: | DE0007251803, DE0007251845, |
WKN: | 725180, 725184, |
Indices: | MDAX |
Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden